Şunu aradınız:: inadvertent foetal exposure (İngilizce - Maltaca)

need to avoid foetal exposure
il-bżonn li jiġi evitat l-espożizzjoni lil fetu

the need to avoid foetal exposure
il-ħtieġa li tiġi evitata l-espożizzjoni tal-fetu

teratogenicity and the need to avoid foetal exposure
teratogeniċità u l-bżonn li tiġi evitata espożizzjoni tal-fetu

the results of most epidemiological studies to date relevant to inadvertent foetal exposure to oestrogens indicate no teratogenic or foetotoxic effects.
ir-riżultati tal-maġġoranza tal-istudji epidemjoloġiċi li saru sal-lum li huma rilevanti għall-esponiment involontarju tal-fetu għall-estroġeni ma jindikaw l-ebda effetti teratoġeniċi jew fetotossiċi.

to avoid potential foetal exposure during pregnancy, a male patient must understand that:
biex jiġi evitat esponiment potenzjali lill-fetu waqt it-tqala, pazjent maskili jrid jifhem li:

foetal exposure in the rats and rabbits was approximately 15 to 20% of that of the mother.
l- espożizzjoni tal- feti tal- firien u tal- fniek kienet ta 'madwar 15 sa 20% ta' dik ta 'l- omm.

information for patients of the teratogenic risks associated with erivedge and the need to avoid foetal exposure
informazzjoni għall-pazjenti dwar ir-riskji ta’ teratoġeniċità assoċjati ma’ erivedge u l-ħtieġa li jiġi evitat esponiment tal-fetu

a requirement to inform patients of the teratogenic risks associated with erivedge and the need to avoid foetal exposure
Ħtieġa li l-pazjenti jiġu nfurmati dwar ir-riskji ta’ teratoġeniċità assoċjati ma’ erivedge u l- ħtieġa li jiġi evitat esponiment tal-fetu

the need to avoid foetal exposure due to teratogenicity of pomalidomide in animals and the expected teratogenic effect of pomalidomide in humans
il-ħtieġa li tiġi evitata l-espożizzjoni tal-fetu minħabba t-teratoġeniċità ta’ pomalidomide fl- annimali u l-effett teratoġeniku mistenni ta’ pomalidomide fil-bnedmin

foetal exposure to bosutinib-derived radioactivity during pregnancy was demonstrated in a placental transfer study in gravid sprague-dawley rats.
l-esponiment tal-fetu għal radjoattività li ġejja minn bosutinib waqt it-tqala kienet murija fl-istudju tat-trasferiment tal-plaċenta fil-firien tat-tip sprague-dawley.

it is not a contract and does not absolve anybody from his/ her responsibilities with regard to the safe use of the product and prevention of foetal exposure .”
mhux kuntratt u ma jassolva lil ħadd mir- responsabbilitajiet tiegħu/ tagħha dwar l- użu sigur tal- prodott u l- prevenzjoni ta ’ l- esponiment tal- fetu. ”

in a separate study wherein entecavir was administered to pregnant lactating rats at 10 mg/kg, both foetal exposure to entecavir and secretion of entecavir into milk were demonstrated.
fi studju separat fejn entecavir ingħata b’doża ta’ 10 mg/kg lil firien tqal u li kienu qed ireddgħu, entecavir instab kemm fil-fetu kif ukoll fil-ħalib tal-omm.

an introduction in each guide will inform the reader that the purpose of the guide is to tell them that a foetal exposure must be avoided and how to minimize the risk of birth defects and miscarriage associated with mycophenolate mofetil.
introduzzjoni f’kull gwida se tgħarraf lill-qarrej li l-għan tal-gwida huwa li tgħidilhom li esponiment tal-fetu għandu jiġi evitat u kif tnaqqas ir-riskju ta’ difetti tat-twelid u ta’ korriment assoċjati ma’ mycophenolate mofetil.

the need to avoid foetal exposure due to teratogenicity of lenalidomide in animals and the expected teratogenic effect of lenalidomide in humans including a summary of the results of study cc-5013- tox-004
il-ħtieġa li tiġi evitata l-espożizzjoni tal-fetu minħabba t-teratoġeniċità ta’ lenalidomide fl- annimali u l-effett teratoġeniku mistenni ta’ lenalidomide fil-bnedmin, li jinkludi sommarju tar-riżultati ta’ studju cc-5013-tox-004

in order to assist health care providers and patients to avoid embryonic and foetal exposure to erivedge the marketing authorisation holder will provide educational materials (erivedge pregnancy prevention programme) to reinforce the potential risks associated with the use of erivedge.
sabiex professjonisti fil-qasam mediku u pazjenti jiġu assistiti biex jevitaw li embrijuni u feti jiġu esposti għal erivedge, id-detentur tal-awtorizzazzjoni għat-tqegħid fis-suq se jipprovdi materjal edukattiv (programm għall-prevenzjoni tat-tqala ta’ erivedge) biex jissaħħaħ it-tagħrif dwar ir-riskji potenzjali assoċjati mal-użu ta’ erivedge.

in order to assist patients in avoiding foetal exposure to lenalidomide, the marketing authorisation holder will provide educational material to health care professionals to reinforce the warnings about the expected teratogenicity of lenalidomide, to provide advice on contraception before therapy is started, and to provide guidance on the need for pregnancy testing.
biex tgħin lil pazjenti jevitaw l-espożizzjoni tal-fetu għal lenalidomide, id-detentur ta’ l- awtorizzazzjoni għat-tqegħid fis-suq ser jipprovdi materjal edukattiv lil professjonisti fil-qasam tas- saħħa biex isaħħaħ it-twissijiet dwar it-teratoġeniċità mistennija ta’ lenalidomide, biex jipprovdi parir fuq il-kontraċezzjoni qabel ma tinbeda t-terapija, u biex jipprovdi gwida fuq il-ħtieġa għall-ittestjar għat-tqala.

o the following information should also be provided in the appropriate booklet female patient of childbearing potential • the need to avoid foetal exposure • the need for effective contraception • that if she needs to change or stop using her method of contraception she should inform:
pazjenti nisa li jistgħu joħorġu tqal

to avoid potential foetal exposure during pregnancy, male patients, even those who have had a vasectomy, must always use a condom (with spermicide, if available) when having sex with a female partner while taking odomzo and for 6 months after the final dose.
sabiex ikun evitat li l-fetu jkun potenzjalment espost matul it-tqala, il-pazjenti rġiel, anke dawk li kellhom vażektomija, għandhom dejjem jużaw kondom (bl-ispermiċida, jekk disponibbli) meta jkollhom x’jaqsmu ma’ mara waqt li qed jieħdu odomzo u għal 6 xhur wara d-doża finali.

pregnancy prevention programme information definition of women of childbearing potential (wcbp) and actions the prescriber should take if childbearing status is unclear information on what is effective contraception safety advice for wcbp • need to avoid foetal exposure • pregnancy prevention requirement, definition and need for adequate contraceptive methods
għall- użu mingħajr periklu ta ’ thalidomide ■ il- ħtieġa li l- pazjenti jingħataw il- materjal edukattiv adattat tal- pazjenti

3 o frequency (before commencing, monthly during treatment and after finishing treatment) • need to stop thalidomide celgene immediately upon suspicion of pregnancy • need to tell treating doctor immediately upon suspicion of pregnancy safety advice for men • the need to avoid foetal exposure • that thalidomide is found in semen and the need to use condoms if sexual partner is pregnant or is a women with childbearing potential not using effective contraception • that if his partner becomes pregnant he should inform his treating doctor immediately and always use a condom during intercourse • that he should not donate semen during therapy and for one week following discontinuation of thalidomide
tagħrif dwar il- programm tal- prevenzjoni tat- tqala o id- definizzjoni ta ’ mara li tista ’ toħroġ tqila (wcbp) u miżuri li min jikteb ir- riċetta medika għandu jieħu jekk l- istatus ta ’ jekk tistax toħroġ tqila mhux ċar tagħrif dwar x’ inhu kontraċettiv effettiv parir dwar is- sigurtà għal wcbp • il- bżonn li jkun evitat l- esponiment tal- fetu • Ħtieġa ta ’ prevenzjoni tat- tqala, definizzjoni u l- bżonn ta ’ metodi kontraċettivi adegwati • jekk għandha bżonn tibdel jew ma tużax aktar il- metodu tagħha ta 'kontraċettiv hi għandha tgħarraf: